Cargando…

Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction

Background: Programmed death-ligand 1 (PD-L1) is expressed not only on some cancer cells, but also on the outer surface of placental syncytiotrophoblasts, which is assumed to induce maternal immune tolerance to fetal tissue via programmed death-1 (PD-1) receptors on T cells. Recently, levels of solu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okuyama, Mai, Mezawa, Hidetoshi, Kawai, Toshinao, Urashima, Mitsuyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387906/ https://www.ncbi.nlm.nih.gov/pubmed/30833943 http://dx.doi.org/10.3389/fimmu.2019.00086

Ejemplares similares

Effect of Avoiding Cow's Milk Formula at Birth on Prevention of Asthma or Recurrent Wheeze Among Young Children: Extended Follow-up From the ABC Randomized Clinical Trial
por: Tachimoto, Hiroshi, et al.
Publicado: (2020)

Vitamin D Supplementation Regulates Postoperative Serum Levels of PD-L1 in Patients with Digestive Tract Cancer and Improves Survivals in the Highest Quintile of PD-L1: A Post Hoc Analysis of the AMATERASU Randomized Controlled Trial
por: Morita, Makoto, et al.
Publicado: (2021)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Serum vitamin D levels and survival of patients with colorectal cancer: Post-hoc analysis of a prospective cohort study
por: Mezawa, Hidetoshi, et al.
Publicado: (2010)

Smoking Is Associated With Low Levels of Soluble PD-L1 in Rheumatoid Arthritis
por: Wasén, Caroline, et al.
Publicado: (2018)

Panoramic snapshot of serum soluble mediator interplay in pregnant women with convalescent COVID-19: an exploratory study
por: Fernandes, Geraldo Magela, et al.
Publicado: (2023)

Reduced Relapse-Free Survival in Colorectal Cancer Patients with Elevated Soluble CD40 Ligand Levels Improved by Vitamin D Supplementation
por: Fujimoto, Hiroshi, et al.
Publicado: (2023)

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
por: Raza, Afsheen, et al.
Publicado: (2023)

The Soluble Form of Toll-Like Receptor 2 Is Elevated in Serum of Multiple Sclerosis Patients: A Novel Potential Disease Biomarker
por: Hossain, Md Jakir, et al.
Publicado: (2018)

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1(+) regulator B cells mediates immunosuppression in triple-negative breast cancer
por: Li, Xuejiao, et al.
Publicado: (2022)

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2020)

Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model
por: Lee, Eun-Ji, et al.
Publicado: (2021)

Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis
por: Ruan, Wei-Shuyi, et al.
Publicado: (2020)

Effect of Vitamin D Supplementation on Survival of Digestive Tract Cancer Patients with Low Bioavailable 25-Hydroxyvitamin D Levels: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial
por: Urashima, Mitsuyoshi, et al.
Publicado: (2020)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Patient-reported outcomes in patients with primary immunodeficiency diseases in Japan: baseline results from a prospective observational study
por: Kanegane, Hirokazu, et al.
Publicado: (2023)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
por: Rotman, Jossie, et al.
Publicado: (2020)

Analysis of the mechanisms regulating soluble PD-1 production and function in human NK cells
por: Mariotti, Francesca Romana, et al.
Publicado: (2023)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
por: Vikerfors, Anders, et al.
Publicado: (2021)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

Targeting the PD-1/PD-L1 Axis in Human Vitiligo
por: Willemsen, Marcella, et al.
Publicado: (2020)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer
por: Aghajani, Marra Jai, et al.
Publicado: (2019)

Elevated Plasma Soluble PD-L1 Levels in Out-of-Hospital Cardiac Arrest Patients
por: Sumiyoshi, Miho, et al.
Publicado: (2021)

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism
por: Raftery, Martin J., et al.
Publicado: (2018)

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
por: Pu, Yunzhou, et al.
Publicado: (2022)

Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance
por: del Rio, Maria-Luisa, et al.
Publicado: (2022)

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
por: Bardhan, Kankana, et al.
Publicado: (2016)

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2018)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
por: Qiao, Xin-wei, et al.
Publicado: (2020)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
por: Chen, Meng, et al.
Publicado: (2022)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
por: Mabbitt, Joseph, et al.
Publicado: (2023)

Human CD8(+)HLA-DR(+) Regulatory T Cells, Similarly to Classical CD4(+)Foxp3(+) Cells, Suppress Immune Responses via PD-1/PD-L1 Axis
por: Machicote, Andres, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tpammm6s8568k7vu4b4i9ifqep